Much has happened at Fujifilm Corp. in recent years, as it has actively built on a promising early start in regenerative medicine, added to its asset base and begun exploiting its growing product development expertise in the pharmaceutical industry.
Indeed, the pace of progress at the Minato-ku, Tokyo group has picked up markedly even since the close of its fiscal year 2015–16 (to March 31, 2016), including the upgrading...
In addition, of late: Fujifilm has tied the knot more firmly with Australian partner Cynata Therapeutics Inc., in which Fujifilm is to own slightly over 10% of the business, following...